A diagnosis of type 1 diabetes in a child is life-changing in the most literal sense: from the day of diagnosis, insulin is required every day, meals require counting, sports require planning, and the family's relationship with food, activity, and sleep changes permanently. It is also a condition that children manage increasingly well, in part because the technology available to them – continuous glucose monitors, smart insulin pumps, closed-loop systems – has transformed practical management in the last decade.
The diagnosis itself is often shocking precisely because it follows a period of apparently normal health. The symptoms build over weeks. A child who seemed merely thirsty, tired, or growing into a growth spurt is suddenly in hospital with DKA, or reaches hospital just before. The fear of DKA, hypoglycaemia, and long-term complications is real and warranted – and so is the realistic outlook that children with well-managed T1D live full, active lives.
Healthbooq (healthbooq.com/apps/healthbooq-kids) covers endocrine conditions and chronic disease management in children.
How Type 1 Diabetes Works
In T1D, the immune system attacks and destroys the beta cells of the pancreatic islets of Langerhans, which produce insulin. The trigger is not fully understood: genetic susceptibility (HLA-DR3 and HLA-DR4 haplotypes confer most risk) interacts with environmental factors, possibly including enteroviral infections. George Eisenbarth at the Joslin Diabetes Center developed the autoimmune staging model (published in NEJM 1986) that remains the framework for understanding T1D progression, now refined into five stages by the JDRF.
Without insulin, glucose cannot enter cells and accumulates in the blood. The body breaks down fat and protein for energy instead, producing ketones. When ketone levels rise, the blood becomes acidic: diabetic ketoacidosis.
Recognising Type 1 Diabetes
The classic presentation – the four Ts – is promoted by Diabetes UK: Toilet (polyuria, going frequently); Thirst (excessive drinking); Tired (unusual fatigue); Thinner (unexplained weight loss). Bedwetting in a previously dry child and recurrent thrush are also common presentations. A blood glucose above 11.1 mmol/L in a symptomatic child confirms the diagnosis.
DKA features include vomiting, abdominal pain, rapid or laboured breathing (Kussmaul breathing), fruity-smelling breath, and altered consciousness. DKA is an emergency. The BSPED (British Society for Paediatric Endocrinology and Diabetes) guidelines for paediatric DKA management are followed in UK centres.
Insulin Regimens
All children with T1D require insulin. There are two main approaches in the UK. The multiple daily injection (MDI) regimen uses a long-acting background insulin once or twice daily, with rapid-acting insulin before each meal or carbohydrate-containing snack, with doses calculated based on carbohydrate content and a carbohydrate-to-insulin ratio. Continuous subcutaneous insulin infusion (CSII), commonly called an insulin pump, delivers a continuous basal rate of rapid-acting insulin and allows bolus delivery at mealtimes. NICE TA151 recommends insulin pump therapy for children under 12 if MDI is considered impractical or inadequate.
Continuous Glucose Monitoring
CGMs measure interstitial glucose every few minutes using a subcutaneous sensor and transmit readings to a phone or reader. The JDRF Juvenile Diabetes Research Foundation funded the key CGM trials (JDRF CGM Study Group, NEJM 2008) that established the clinical benefit of CGM in reducing HbA1c and time in hypoglycaemia. NHS England now funds CGM for all children with T1D.
Hybrid closed-loop systems – where a CGM communicates directly with an insulin pump and an algorithm automatically adjusts insulin delivery – are now available on the NHS (CamAPS FX, the Cambridge system, received CE marking in 2020). Roman Hovorka at the University of Cambridge led the clinical trial programme. These systems substantially reduce the burden of management and improve time in range.
Hypoglycaemia
Hypoglycaemia (blood glucose below 4 mmol/L) is the most common acute complication. Symptoms in children: shaking, sweating, pallor, confusion, irritability, hunger. Mild-to-moderate hypos are treated with fast-acting carbohydrate (15g): glucose tablets, Lucozade, or fruit juice, followed by a longer-acting snack. Severe hypoglycaemia with unconsciousness or seizure is treated with glucagon injection (GlucaGen) or nasal glucagon (Baqsimi), which can be administered by a trained parent, school staff, or bystander.
Children at risk of severe hypos should have glucagon at home and at school, with trained adults in both settings.
School and Daily Life
Type 1 diabetes requires management throughout the school day: glucose checks (or CGM review), insulin for lunch, treatment of hypos if they occur, and adjustments for physical activity. The Children and Families Act 2014 places a duty on schools to support children with medical conditions. Every child with T1D is entitled to an individual healthcare plan (IHP), developed with the school, family, and diabetes team.
Sports lower blood glucose during and after exercise. Children and adolescents are taught to check glucose before activity, reduce pre-activity insulin, and have fast-acting carbohydrate available. The principles are the same across sport types; the practical adjustments vary.
Long-Term Management
The DCCT (Diabetes Control and Complications Trial, NEJM 1993) established that intensive glycaemic control – keeping HbA1c as low as safely possible – dramatically reduces the long-term complications of T1D: retinopathy, nephropathy, and neuropathy. The target HbA1c in the UK for children is below 48 mmol/mol (6.5%), with recognition that this is a guide rather than a threshold, and that avoiding severe hypoglycaemia and supporting quality of life are also clinical priorities.
Annual review includes HbA1c, blood pressure, lipids, thyroid function (autoimmune thyroid disease co-occurs in 17-30% of T1D), coeliac screen (co-occurs in 5-10%), and urine microalbumin (to screen for early nephropathy, from age 12 or after 5 years' duration).
Adolescence is a consistently difficult period for T1D management. Insulin resistance rises with puberty; the social demands of adolescence conflict with visible diabetes management; disordered eating and insulin omission for weight control (diabulimia) are a recognised risk. Transition to adult services is a high-risk period and requires careful planning.
Key Takeaways
Type 1 diabetes (T1D) is an autoimmune condition in which the insulin-producing beta cells of the pancreas are destroyed, requiring lifelong insulin replacement. It is the most common endocrine condition of childhood, affecting approximately 1 in 500 UK children. Diagnosis typically occurs after a period of symptom build-up (thirst, polyuria, weight loss, fatigue) and is confirmed by blood glucose and ketone testing. Without prompt treatment, diabetic ketoacidosis (DKA) can develop rapidly and be life-threatening. Modern management uses basal-bolus insulin regimens or insulin pumps with continuous glucose monitors (CGMs), aiming for HbA1c below 48 mmol/mol (6.5%) while minimising hypoglycaemia and supporting normal childhood development.
